White label ELPA - ClinicalTrials.eu

Study on Belzutifan for Treating Kidney Cancer in Patients with von Hippel-Lindau Disease

Not recruiting

2 1 1
Investigated diseases:
- Von Hippel-Lindau disease
Investigated drugs:
- Belzutifan
Study on the Safety of Lutetium (177Lu) Oxodotreotide, L-Lysine Hydrochloride, and L-Arginine Hydrochloride in Adolescents with Neuroendocrine Tumors and PPGLs

Not recruiting

2 1 1 1
Investigated diseases:
Investigated drugs:
Study on Esketamine and Propofol for Anesthesia in Electroconvulsive Therapy for Patients with Major Depression

Not recruiting

3 1 1 1
Investigated diseases:
- Major depression
Investigated drugs:
Study of iberdomide alone or with drug combinations for patients with multiple myeloma: testing safety and effectiveness of different doses

Not recruiting

1 1 1 1
Investigated diseases:
- Plasma cell myeloma
Investigated drugs:
Study on Improving Knee Implant Stability in Osteoarthritis Patients Using Denosumab and Zoledronic Acid

Not recruiting

2 1 1
Investigated diseases:
- Osteoarthritis
Investigated drugs:
Study on the Safety and Effects of Durvalumab and Tremelimumab with Radiotherapy for Patients with Metastatic Squamous Cell Carcinoma

Not recruiting

1 1 1 1
Investigated diseases:
Investigated drugs:
- Tremelimumab
- Durvalumab
Study on Canakinumab for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes or MDS/MPN

Not recruiting

2 1 1 1
Investigated diseases:
- Anaemia
- Myelodysplastic syndrome
Investigated drugs:
- Canakinumab
Study of Atezolizumab and Tiragolumab Compared to Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemoradiation

Not recruiting

3 1 1 1
Investigated diseases:
- Non-small cell lung cancer stage III
Investigated drugs:
- Atezolizumab
- Durvalumab
+5
Study of Taldefgrobep Alfa for Patients with Spinal Muscular Atrophy on Stable Nusinersen and/or Risdiplam Regimen or with Onasemnogene Abeparvovec-xioi History

Not recruiting

3 1
Investigated diseases:
- Spinal muscular atrophy
Investigated drugs:
- Taldefgrobep Alfa
+1
Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Not recruiting

3 1 1 1
Investigated diseases:
- HER2 positive breast cancer
Investigated drugs:
- Trastuzumab Deruxtecan
- Trastuzumab Emtansine
+7

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies